Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Simcere Pharmaceutical Receives First Generic Biapenem Certificate

This article was originally published in PharmAsia News

Executive Summary

Simcere Pharmaceutical Group's first generic biapenem drug has received new drug certificate and production approval from China's State FDA. A newly launched generic drug enjoys a four-year assessment grace period during which SFDA declines applications of similar chemical compounds or drug administration routes whose R&D has not entered into clinical stages. Biapenem, like Merck's Tienam and Dainippon Sumitomo's Mepem, comes under carbapenem antibiotics. The drugs have a 1.6 billion yuan market in China, with 30 percent annual growth over the past three years. Simcere believes that the biapenem's approval will enhance the firm's long-term strategy of focusing on first-to-market anti-infection generic drugs. (Click here for more - Chinese Language)
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC068499

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel